Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Inventiva S.A.

$3.91 -2.98% NASDAQ: IVA · 15-min delayed
  • Public · NASDAQ: IVA
  • 77 employees
$842.1MMarket cap
77Employees
IVANASDAQ
2020IPO

About Inventiva S.A.

Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Market cap
$842.1M
NASDAQ: IVA
$3.91 -2.98%

15-minute delayed · data by Polygon.io

Past year

$2.98 $7.15

52-week range

Market cap
$842.1M
Shares outstanding
215.4M
Open
Day range
Prev close
Volume
IPO date
Jul 10, 2020

Market data by Polygon.io · prices are 15-minute delayed

Auto-generated

At a glance

  • Trading 45% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Inventiva S.A..

Write a review
Newsroom

News about Inventiva S.A.

News & sentiment via Polygon.io

Explore

Similar companies

Browse all →